Dapagliflozin is associated with improved glycaemic control and weight reduction at 44 months of follow-up in a secondary care diabetes clinic in the UK.
Aged
Benzhydryl Compounds
/ therapeutic use
Diabetes Mellitus, Type 2
/ drug therapy
Female
Follow-Up Studies
Glucosides
/ therapeutic use
Glycated Hemoglobin
/ analysis
Glycemic Control
Humans
Hypoglycemic Agents
/ therapeutic use
Male
Middle Aged
Secondary Care
Treatment Outcome
United Kingdom
Weight Loss
/ drug effects
Cardiovascular
Dapagliflozin
HbA1c
SGLT2 inhibitor
Journal
Diabetes & metabolic syndrome
ISSN: 1878-0334
Titre abrégé: Diabetes Metab Syndr
Pays: Netherlands
ID NLM: 101462250
Informations de publication
Date de publication:
Historique:
received:
21
02
2020
revised:
18
03
2020
accepted:
19
03
2020
pubmed:
5
4
2020
medline:
27
2
2021
entrez:
5
4
2020
Statut:
ppublish
Résumé
We examined HbA1c and cardiovascular risk factors with a median follow-up of 44 months therapy with dapagliflozin. We undertook a clinical practice evaluation of 101 patients attending our clinic. Dapagliflozin resulted in a significant reduction in HbA1c 82.6 ± 15.7 v 68.7 ± 17.8 mmol/mol. Dapagliflozin maintains glycaemic control along with sustained improvements in weight and no decline in renal function.
Sections du résumé
BACKGROUND AND AIMS
OBJECTIVE
We examined HbA1c and cardiovascular risk factors with a median follow-up of 44 months therapy with dapagliflozin.
METHODS
METHODS
We undertook a clinical practice evaluation of 101 patients attending our clinic.
RESULTS
RESULTS
Dapagliflozin resulted in a significant reduction in HbA1c 82.6 ± 15.7 v 68.7 ± 17.8 mmol/mol.
CONCLUSION
CONCLUSIONS
Dapagliflozin maintains glycaemic control along with sustained improvements in weight and no decline in renal function.
Identifiants
pubmed: 32247210
pii: S1871-4021(20)30047-3
doi: 10.1016/j.dsx.2020.03.007
pii:
doi:
Substances chimiques
Benzhydryl Compounds
0
Glucosides
0
Glycated Hemoglobin A
0
Hypoglycemic Agents
0
dapagliflozin
1ULL0QJ8UC
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
237-239Informations de copyright
Crown Copyright © 2020. Published by Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest Professor Stephens has received research funding from Astra Zeneca for different work along with speaker fees.